Table 3 summary of four different studies that investigated the potential of using exosomal miRNAs as biomarkers for diagnosis

From: MicroRNAs regulation in Parkinson’s disease, and their potential role as diagnostic and therapeutic targets

Study

PD group(n)

Control(n)

Exosome source

RNA extraction

RNA identification

miRNAs expression

Exosomal miRNAs

Accuracy of diagnosis(AUC)

Gui et al. 115

47

27

CSF

Qiagen miRNeasy Serum/Plasma Kit

TaqMan Real-Time PCR

Upregulated

ex- miR-10a-5p

0.900

ex-miR-153

0.780

ex-miR-409-3p

0.970

Downregulated

ex-miR-1

0.920

ex-miR-19b-3p

0.705

Cao et al. 105

109

40

Serum

miRNeasy Mini Kit

RT-PCR followed by qPCR

Upregulated

miR-24

0.908

miR-195

0.697

Downregulated

miR-19b

0.753

Yao et al. 147

52

48

Plasma

Exosomal RNA and Protein Extraction kit

RT-qPCR

Upregulated

ex-miR-331-5p

0.849

Downregulated

ex-miR-505

0.898

Barbagallo et al. 148

30

30

Serum

miRNeasy Mini-Kit (Qiagen)

TaqMan RT-PCR

Upregulated

ex-let-7d,

0.753

ex-miR-22

0.845

ex- miR-23a

0.869

ex-miR-24

0.779

ex- miR-142-3p

0.783

and ex-miR-222

0.816

  1. miR/miRNA microRNA, PD Parkinson’s disease, AUC area under the curve, CSF cerebrospinal fluid, RT-qPCR quantitative reverse transcription polymerase chain reaction.
Back to article page